A Unified Program Integrity Contractor (UPIC) audit of a physician practice or laboratory billing cancer genomic panels rarely starts with a single flagged claim. In September 2019, DOJ charged 35 defendants with more than $2.1 billion in fraudulent hereditary cancer genetic testing claims, built on telemarketing recruiters and kickbacks paid to ordering physicians. UPIC reviewers now approach a genetic testing claim with the same three questions that case built: was the panel medically necessary for this specific patient, did the ordering physician have an actual treating relationship with the beneficiary, and did a telemarketing or lead-generation arrangement sit behind the referral. A provider that cannot answer all three risks an extrapolated recoupment demand or a referral for criminal investigation.
Cancer Genomic Panel Billing and Medical Necessity Documentation
Laboratories billing hereditary cancer and other genomic panels operate under the MolDX program, administered by Palmetto GBA and adopted by Medicare Administrative Contractors nationwide. The governing local coverage determination for lab-developed tests for inherited cancer syndromes requires the ordering record to document a personal or family history, or another clinical indication, that meets the coverage criteria for the specific panel billed, not a general screening rationale. Medicare's treating-physician rule adds a second layer: under 42 CFR 410.32, a diagnostic test is reasonable and necessary only when ordered by the physician actually treating the patient. A genomic panel ordered by a physician who never examined the patient or discussed the results fails this standard regardless of how the laboratory processed the specimen.
Telemarketing-Driven Referrals and the Ordering Physician Relationship
The 2019 genetic testing cases relied on a consistent structure: telemarketers and call centers recruited Medicare beneficiaries with offers of a free cancer risk screening, then routed a pre-filled order to a physician, often one with no prior relationship to the patient, in exchange for a per-order payment. HHS-OIG's 2022 Special Fraud Alert on telemedicine arrangements names genetic testing directly among the suspect fact patterns, flagging consults where the practitioner signs a pre-filled order without an exam or chart review. A UPIC auditing a practice or telehealth platform pulls the intake call record, the consult note, and the signature log together, and a mismatch between a brief telephone consult and a signed order for an expensive panel is the pattern reviewers are trained to isolate.
A genomic panel ordered without an examination, a chart review, or a documented treating relationship is a marketing outcome, not a medical decision, and UPIC reviewers are trained to see the difference.
Anti-Kickback and EKRA Exposure in Genetic Testing Marketing
Two federal kickback statutes converge on the genetic testing marketing model. The federal Anti-Kickback Statute (AKS) reaches remuneration paid to induce a referral for a service reimbursed by a federal healthcare program, which covers payments from a laboratory to a physician, a call center, or a marketing agency tied to the volume of genetic testing orders generated. The Eliminating Kickbacks in Recovery Act (EKRA) extends criminal exposure to laboratory marketing arrangements, including commission-based payments to sales representatives and recruiters, without the AKS requirement that a federal program actually pay the claim. A UPIC that identifies a percentage-based or per-lead payment structure behind a physician's genetic testing referrals routinely shares that finding with OIG and DOJ for parallel review under both statutes.
When a UPIC Audit Escalates to Recoupment or Referral
A UPIC that finds an unacceptable error rate in the sampled orders can extrapolate that rate across the full lookback period, turning a review of a few dozen requisitions into a seven-figure recoupment demand. Rebuttal and appeal deadlines are short, and claims can move to prepayment review while the matter is pending, cutting off reimbursement while the recoupment clock runs. A pattern traced to a marketing arrangement rather than an isolated documentation gap can also draw a target letter and a referral for criminal investigation. Providers navigating this posture should review our companion guides on UPIC prepayment review, responding to a UPIC records request, and preparing for a UPIC site visit.
Why Early Legal Counsel Is Critical
It is critical that physicians, laboratories, and telehealth platforms promptly retain experienced healthcare defense counsel upon receiving a UPIC audit notice, additional documentation request, or other government inquiry into genetic testing billing or referral sources. Early legal intervention can protect the provider's rights, ensure the response addresses both the medical necessity record and the extrapolation methodology at issue, avoid inadvertent admissions, and preserve defenses that may otherwise be lost. Delaying representation can significantly affect the outcome of the matter.
How Health Law Alliance Can Help
Health Law Alliance defends physicians, laboratories, and telehealth platforms against UPIC audits of cancer genomic panel billing, ordering physician relationships, and telemarketing-driven referral arrangements, including disputes over extrapolated recoupment demands and Anti-Kickback Statute or EKRA exposure tied to marketing agreements. Our bench includes a former federal prosecutor and a former senior healthcare compliance executive, background that shapes how we evaluate which sampled orders and referral relationships are defensible before an appeal is filed. If your practice or laboratory has received a UPIC audit notice tied to genetic testing, contact us for a free, confidential consultation.
